Assessment of Capecitabine and Bevacizumab With or Without Atezolizumab for the Treatment of Refractory Metastatic Colorectal Cancer | Zendy

Niharika B. Mettu | Zendy; FangShu Ou | Zendy; Tyler Zemla | Zendy; Þorvarður R. Hálfdánarson | Zendy; HeinzJosef Lenz | Zendy; Rimini Breakstone | Zendy; Patrick M. Boland | Zendy; Oxana Crysler | Zendy; Christina Wu | Zendy; Andrew B. Nixon | Zendy; Emily Bolch | Zendy; Doniedzwiecki | Zendy; Alicia Elsing | Zendy; Herbert I. Hurwitz | Zendy; Marwan Fakih | Zendy; Tanios BekaiiSaab | Zendy

Open Access

Assessment of Capecitabine and Bevacizumab With or Without Atezolizumab for the Treatment of Refractory Metastatic Colorectal Cancer

Author(s) -

Niharika B. Mettu,

FangShu Ou,

Tyler Zemla,

Þorvarður R. Hálfdánarson,

HeinzJosef Lenz,

Rimini Breakstone,

Patrick M. Boland,

Oxana Crysler,

Christina Wu,

Andrew B. Nixon,

Emily Bolch,

Doniedzwiecki,

Alicia Elsing,

Herbert I. Hurwitz,

Marwan Fakih,

Tanios BekaiiSaab

Publication year - 2022

Publication title -

jama network open

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.278

H-Index - 39

ISSN - 2574-3805

DOI - 10.1001/jamanetworkopen.2021.49040

Subject(s) - bevacizumab , medicine , capecitabine , atezolizumab , irinotecan , oncology , oxaliplatin , colorectal cancer , clinical endpoint , hazard ratio , cancer , chemotherapy , randomized controlled trial , nivolumab , immunotherapy , confidence interval

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom

About

About Careers Publisher Partners Contact Us Our institutional solutions Get Organisational Trial or Quote

Learn

FAQs Blog Terms of Use Privacy Policy

Download the Zendy App

Discover

Explore

Home ZAIA Blog